Filing Details

Accession Number:
0001104659-20-032715
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-03-12 21:39:06
Reporting Period:
2020-03-10
Accepted Time:
2020-03-12 21:39:06
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1175151 Cytosorbents Corp CTSO Surgical & Medical Instruments & Apparatus (3841) 980373793
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1368151 Vincent Capponi C/O Cytosorbents Corporation
7 Deer Park Drive, Suite K
Monmouth Junction NJ 08852
Chief Operating Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-03-10 6,500 $3.45 417,649 No 4 M Direct
Common Stock Acquisiton 2020-03-10 4,677 $3.45 422,326 No 4 M Direct
Common Stock Disposition 2020-03-10 4,677 $6.00 417,649 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2020-03-10 6,500 $0.00 6,500 $3.45
Common Stock Stock Option (right to buy) Disposition 2020-03-10 4,677 $0.00 4,677 $3.45
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
14,800 2020-05-05 No 4 M Direct
10,123 2020-05-05 No 4 M Direct
Footnotes
  1. Stock option exercise conducted pursuant to a 10b5-1 trading plan adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").
  2. Open market sale conducted pursuant to a 10b5-1 trading plan adopted by the reporting person in accordance with Rule 10b5-1 of the Exchange Act.
  3. Includes: (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 17,900 RSUs granted on February 24, 2017, (b) 54,000 RSUs granted on June 7, 2016, (c) 125,000 RSUs granted on April 8, 2015 and (d) 10,100 RSUs granted on March 15, 2018; and (ii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into common stock, par value $0.001 per share (the "Common Stock") of the Company upon vesting: (a) 36,067 RSUs granted on February 28, 2020 and unvested on the date hereof; (b) 36,067 RSUs granted on July 22, 2019 and unvested on the date hereof; (continued in footnote 4)
  4. (continued from footnote 3) and (c) 1,540 RSUs granted on March 4, 2019 and unvested on the date hereof; and (iii) 136,975 shares of common stock owned by the reporting person.
  5. These stock options were originally granted on May 5, 2010 and vested at the discretion of the Company's Board of Directors based on satisfying certain criteria including a timely completion of the sepsis trial, raising capital for the Company, and partnering and business development.